ATE433961T1 - Ansamycine mit verbesserten pharmakologischen und biologischen eigenschaften - Google Patents
Ansamycine mit verbesserten pharmakologischen und biologischen eigenschaftenInfo
- Publication number
- ATE433961T1 ATE433961T1 AT03713437T AT03713437T ATE433961T1 AT E433961 T1 ATE433961 T1 AT E433961T1 AT 03713437 T AT03713437 T AT 03713437T AT 03713437 T AT03713437 T AT 03713437T AT E433961 T1 ATE433961 T1 AT E433961T1
- Authority
- AT
- Austria
- Prior art keywords
- ansamycins
- biological properties
- improved pharmacological
- dimers
- prodrugs
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
- C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/5532—Seven-(or more) membered rings
- C07F9/5535—Seven-(or more) membered rings condensed with carbocyclic rings or ring systems
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35527502P | 2002-02-08 | 2002-02-08 | |
US36705502P | 2002-03-22 | 2002-03-22 | |
PCT/US2002/039993 WO2003050295A2 (en) | 2001-12-12 | 2002-12-12 | Assays and implements for determining and modulating hsp90 binding activity |
PCT/US2003/004283 WO2003066005A2 (en) | 2002-02-08 | 2003-02-10 | Ansamycins having improved pharmacological and biological properties |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE433961T1 true ATE433961T1 (de) | 2009-07-15 |
Family
ID=40794734
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03713437T ATE433961T1 (de) | 2002-02-08 | 2003-02-10 | Ansamycine mit verbesserten pharmakologischen und biologischen eigenschaften |
Country Status (8)
Country | Link |
---|---|
US (1) | US7465718B2 (de) |
EP (1) | EP1472230B1 (de) |
JP (1) | JP2005530689A (de) |
AT (1) | ATE433961T1 (de) |
AU (1) | AU2003217393B8 (de) |
CA (1) | CA2474508A1 (de) |
DE (1) | DE60327994D1 (de) |
WO (1) | WO2003066005A2 (de) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6872715B2 (en) | 2001-08-06 | 2005-03-29 | Kosan Biosciences, Inc. | Benzoquinone ansamycins |
JP2005530689A (ja) | 2002-02-08 | 2005-10-13 | コンフォーマ・セラピューティクス・コーポレイション | 改良された薬理学的および生物学的特性を有するアンサマイシン |
EP1492522A4 (de) * | 2002-04-10 | 2009-01-14 | Conforma Therapeutics Corp | Ansamycin-formulierungen und verfahren zu ihrer herstellung und verwendung |
JP4942915B2 (ja) | 2002-04-26 | 2012-05-30 | ギリアード サイエンシーズ, インコーポレイテッド | Hivプロテアーゼ阻害剤化合物のホスホネートアナログの細胞蓄積 |
US7407965B2 (en) | 2003-04-25 | 2008-08-05 | Gilead Sciences, Inc. | Phosphonate analogs for treating metabolic diseases |
WO2005002626A2 (en) | 2003-04-25 | 2005-01-13 | Gilead Sciences, Inc. | Therapeutic phosphonate compounds |
US7470724B2 (en) | 2003-04-25 | 2008-12-30 | Gilead Sciences, Inc. | Phosphonate compounds having immuno-modulatory activity |
US7452901B2 (en) | 2003-04-25 | 2008-11-18 | Gilead Sciences, Inc. | Anti-cancer phosphonate analogs |
US7300924B2 (en) | 2003-04-25 | 2007-11-27 | Gilead Sciences, Inc. | Anti-infective phosphonate analogs |
CA2522845A1 (en) | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Kinase inhibitor phosphonate conjugates |
US7432261B2 (en) | 2003-04-25 | 2008-10-07 | Gilead Sciences, Inc. | Anti-inflammatory phosphonate compounds |
EP1628685B1 (de) | 2003-04-25 | 2010-12-08 | Gilead Sciences, Inc. | Antivirale phosphonate analoge |
US7427636B2 (en) | 2003-04-25 | 2008-09-23 | Gilead Sciences, Inc. | Inosine monophosphate dehydrogenase inhibitory phosphonate compounds |
US7241754B2 (en) | 2003-06-13 | 2007-07-10 | Kosan Biosciences, Inc. | 2-Desmethyl ansamycin compounds |
CA2543294A1 (en) | 2003-10-24 | 2005-05-26 | Gilead Sciences, Inc. | Methods and compositions for identifying therapeutic compounds |
WO2005044279A1 (en) | 2003-10-24 | 2005-05-19 | Gilead Sciences, Inc. | Purine nucleoside phosphonate conjugates |
WO2005044308A1 (en) | 2003-10-24 | 2005-05-19 | Gilead Sciences, Inc. | Phosphonate analogs of antimetabolites |
US6855705B1 (en) | 2003-11-12 | 2005-02-15 | Kosan Biosciences, Inc. | 11-O-methylgeldanamycin compounds |
US6887993B1 (en) | 2003-11-12 | 2005-05-03 | Kosan Biosciences, Inc. | 11-O-methylgeldanamycin compounds |
JP4717003B2 (ja) * | 2003-11-12 | 2011-07-06 | コーサン バイオサイエンシーズ, インコーポレイテッド | 11−o−メチルゲルダナマイシン化合物 |
US6875863B1 (en) | 2003-11-12 | 2005-04-05 | Kosan Biosciences, Inc. | 11-O-methylgeldanamycin compounds |
EP1706405B1 (de) | 2003-12-22 | 2009-03-04 | Gilead Sciences, Inc. | 4'-substituierte carbovir- und abacavir-derivate sowie verwandte verbindungen mit hiv- und hcv-antiviraler wirkung |
US20060019941A1 (en) * | 2003-12-23 | 2006-01-26 | Infinity Pharmaceuticals, Inc. | Analogs of benzoquinone-containing ansamycins and methods of use thereof |
US7282493B2 (en) * | 2003-12-23 | 2007-10-16 | Infinity Pharmaceuticals, Inc. | Analogs of benzoquinone-containing ansamycins and methods of use thereof |
DE10361944A1 (de) * | 2003-12-31 | 2005-07-28 | Viromics Gmbh | Mittel zur Hemmung der Virusreplikation durch Regulation der Proteinfaltung |
JP2007530596A (ja) * | 2004-03-26 | 2007-11-01 | バン アンデル リサーチ インスティチュート | ゲルダナマイシンおよび誘導体はガン浸潤を阻害し、新規な標的を同定する |
US7259156B2 (en) | 2004-05-20 | 2007-08-21 | Kosan Biosciences Incorporated | Geldanamycin compounds and method of use |
NZ553405A (en) | 2004-07-27 | 2010-03-26 | Gilead Sciences Inc | Nucleoside phosphonate conjugates as anti-HIV agents |
US20080171687A1 (en) * | 2004-09-16 | 2008-07-17 | Abraxis Bioscience, Inc. | Compositions And Methods For The Preparation And Administration Of Poorly Water Soluble Drugs |
US20060067953A1 (en) * | 2004-09-29 | 2006-03-30 | Conforma Therapeutics Corporation | Oral pharmaceutical formulations and methods for producing and using same |
WO2006050457A2 (en) * | 2004-11-02 | 2006-05-11 | Conforma Therapeutics Corporation | Methods and compositions for treating chronic lymphocytic leukemia |
US7608611B2 (en) | 2005-03-11 | 2009-10-27 | The Regents Of The University Of Colorado | Hsp90 inhibitors, methods of making and uses therefor |
EP1906950A4 (de) * | 2005-06-21 | 2008-09-24 | Infinity Discovery Inc | Ansamycin-formulierungen und anwendungsverfahren dafür |
WO2007001049A1 (ja) * | 2005-06-29 | 2007-01-04 | Kyowa Hakko Kogyo Co., Ltd. | ベンゼノイドアンサマイシン誘導体 |
AU2006320435A1 (en) * | 2005-12-01 | 2007-06-07 | Conforma Therapeutics Corporation | Compositions containing ansamycin |
AR061185A1 (es) | 2006-05-26 | 2008-08-13 | Chugai Pharmaceutical Co Ltd | Compuestos heterociclicos como inhibidores de hsp90. composiciones farmaceuticas. |
WO2008056188A2 (en) * | 2006-11-09 | 2008-05-15 | Biotica Technology Limited | Novel compounds and methods for their production |
PE20081506A1 (es) | 2006-12-12 | 2008-12-09 | Infinity Discovery Inc | Formulaciones de ansamicina |
MX2009008756A (es) | 2007-03-01 | 2009-08-27 | Chugai Pharmaceutical Co Ltd | Compuesto macrociclico. |
AU2008240179A1 (en) * | 2007-04-12 | 2008-10-23 | Infinity Discovery, Inc. | Hydroquinone ansamycin formulations |
EP2190291B1 (de) | 2007-08-23 | 2015-10-14 | The Regents of The University of Colorado, A Body Corporate | Hsp90-hemmer mit modifizierter toxizität |
WO2009036092A2 (en) | 2007-09-10 | 2009-03-19 | University Of Massachusetts | Mitochondria-targeted anti-tumor agents |
CN101220068B (zh) * | 2008-01-18 | 2012-06-13 | 中国医学科学院医药生物技术研究所 | 一组格尔德霉素衍生物及其制备方法 |
US20090186039A1 (en) * | 2008-01-18 | 2009-07-23 | Jang Sung-Key | Novel use of grp 94 in virus infection |
US8658617B2 (en) | 2008-07-08 | 2014-02-25 | Gilead Sciences, Inc. | Salts of HIV inhibitor compounds |
EP2348845A4 (de) | 2008-10-15 | 2013-01-23 | Infinity Pharmaceuticals Inc | Ansamycin-hydrochinon-zusammensetzungen |
US20110201587A1 (en) * | 2010-02-16 | 2011-08-18 | Bio Holding, Inc. | Hsp90 inhibitors and methods of use |
WO2013074695A1 (en) | 2011-11-14 | 2013-05-23 | The Regents Of The University Of Colorado, A Body Corporate | Hsp90 inhibitors with modified toxicity |
US10851125B2 (en) | 2017-08-01 | 2020-12-01 | Gilead Sciences, Inc. | Crystalline forms of ethyl ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl(-L-alaninate |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3595955A (en) * | 1969-03-26 | 1971-07-27 | Upjohn Co | Geldanamycin and process for producing same |
US4261989A (en) * | 1979-02-19 | 1981-04-14 | Kaken Chemical Co. Ltd. | Geldanamycin derivatives and antitumor drug |
US4699877A (en) * | 1982-11-04 | 1987-10-13 | The Regents Of The University Of California | Methods and compositions for detecting human tumors |
US4918162A (en) * | 1986-05-06 | 1990-04-17 | The Regents Of The University Of California | Assays and antibodies for N-MYC proteins |
US4968603A (en) * | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
US4975278A (en) * | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
US5627165A (en) * | 1990-06-13 | 1997-05-06 | Drug Innovation & Design, Inc. | Phosphorous prodrugs and therapeutic delivery systems using same |
WO1993014215A1 (en) | 1992-01-06 | 1993-07-22 | Pfizer Inc. | Process and uses for 4,5-dihydrogeldanamycin and its hydroquinone |
US5387584A (en) * | 1993-04-07 | 1995-02-07 | Pfizer Inc. | Bicyclic ansamycins |
CA2166320A1 (en) | 1993-06-29 | 1995-01-12 | Randall James Gallaschun | Ansamycin derivatives as antioncogene and anticancer agents |
US5932566A (en) * | 1994-06-16 | 1999-08-03 | Pfizer Inc. | Ansamycin derivatives as antioncogene and anticancer agents |
US5846749A (en) * | 1994-10-12 | 1998-12-08 | The Regents Of The University Of California | Quantitative measurement of tissue protein identified by immunohistochemistry and standardized protein determination |
AU741439B2 (en) * | 1996-12-30 | 2001-11-29 | Battelle Memorial Institute | Formulation and method for treating neoplasms by inhalation |
DE69841549D1 (de) | 1997-05-14 | 2010-04-22 | Sloan Kettering Inst Cancer | Verfahren und zubereitungen zur zerstörung bestimmter proteine |
US5968921A (en) * | 1997-10-24 | 1999-10-19 | Orgegon Health Sciences University | Compositions and methods for promoting nerve regeneration |
AU3378599A (en) | 1998-04-03 | 1999-10-25 | University Of Pittsburgh | Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke |
US6174875B1 (en) * | 1999-04-01 | 2001-01-16 | University Of Pittsburgh | Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke |
WO2001072779A1 (en) | 2000-03-24 | 2001-10-04 | Duke University | Characterization of grp94-ligand interactions and purification, screening, and therapeutic methods relating thereto |
WO2002002123A1 (en) | 2000-06-29 | 2002-01-10 | Trustees Of Boston University | Use of geldanamycin and related compounds for prophylaxis or treatment of fibrogenic disorders |
US6946456B2 (en) | 2000-07-28 | 2005-09-20 | Sloan-Kettering Institute For Cancer Research | Methods for treating cell proliferative disorders and viral infections |
JP2005519848A (ja) | 2000-11-02 | 2005-07-07 | スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ | Hsp90に結合するための小分子組成物 |
KR20030065502A (ko) | 2000-11-02 | 2003-08-06 | 슬로안-케테링인스티튜트퍼캔서리서치 | 에이치에스피90 저해제를 이용한 세포독성 제제의 효능을향상시키는 방법 |
WO2002069900A2 (en) | 2001-03-01 | 2002-09-12 | Conforma Therapeutics Corp. | Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors |
EP1404871A4 (de) | 2001-05-23 | 2006-10-04 | Sloan Kettering Inst Cancer | Methode zur behandlung von krebs im zusammenhang mit erhöhten her 2 werten |
CN100378079C (zh) | 2001-09-24 | 2008-04-02 | 康福玛医药公司 | 用于制备17-烯丙基氨基格尔德霉素(17-aag)以及其它袢霉素的方法 |
EP1440072A4 (de) | 2001-10-30 | 2005-02-02 | Conforma Therapeutic Corp | Purinanaloga mit hsp90-inhibierender wirkung |
US7553979B2 (en) | 2001-11-09 | 2009-06-30 | Conforma Therapeutics Corporation | HSP90-inhibiting zearalanol compounds and methods of producing and using same |
US20050074457A1 (en) | 2001-12-12 | 2005-04-07 | Adeela Kamal | Assays and implements for determining and modulating hsp90 binding activity |
JP2005530689A (ja) | 2002-02-08 | 2005-10-13 | コンフォーマ・セラピューティクス・コーポレイション | 改良された薬理学的および生物学的特性を有するアンサマイシン |
TW200303363A (en) | 2002-02-25 | 2003-09-01 | Upjohn Co | Process to prepare and isolate geldanamycin |
-
2003
- 2003-02-10 JP JP2003565431A patent/JP2005530689A/ja not_active Withdrawn
- 2003-02-10 US US10/503,880 patent/US7465718B2/en not_active Expired - Fee Related
- 2003-02-10 AT AT03713437T patent/ATE433961T1/de not_active IP Right Cessation
- 2003-02-10 AU AU2003217393A patent/AU2003217393B8/en not_active Ceased
- 2003-02-10 WO PCT/US2003/004283 patent/WO2003066005A2/en active Application Filing
- 2003-02-10 DE DE60327994T patent/DE60327994D1/de not_active Expired - Lifetime
- 2003-02-10 EP EP03713437A patent/EP1472230B1/de not_active Expired - Lifetime
- 2003-02-10 CA CA002474508A patent/CA2474508A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US7465718B2 (en) | 2008-12-16 |
AU2003217393B8 (en) | 2009-06-25 |
JP2005530689A (ja) | 2005-10-13 |
AU2003217393A1 (en) | 2003-09-02 |
EP1472230B1 (de) | 2009-06-17 |
EP1472230A2 (de) | 2004-11-03 |
WO2003066005A3 (en) | 2004-06-10 |
CA2474508A1 (en) | 2003-08-14 |
WO2003066005A2 (en) | 2003-08-14 |
AU2003217393B2 (en) | 2009-02-26 |
EP1472230A4 (de) | 2005-07-06 |
DE60327994D1 (de) | 2009-07-30 |
US20050267122A1 (en) | 2005-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60327994D1 (de) | Ansamycine mit verbesserten pharmakologischen und biologischen eigenschaften | |
CY1120257T1 (el) | ΠΥΡΡΟΛΟ[2,3b]ΠΥΡΙΔΙΝ-4-ΥΛΑΜΙΝΕΣ ΚΑΙ ΠΥΡΡΟΛΟ[2,3b]ΠΥΡΙΜΙΔΙΝ-4-ΥΛΑΜΙΝΕΣ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΚΙΝΑΣΩΝ JANUS | |
CY1110914T1 (el) | Δικυκλο-πυραζολες δραστικες ως αναστολεις kinασων, διεργασια για την παρασκευη τους και φαρμακευτικες συνθεσεις που τις περιλαμβανουν | |
CY2014008I1 (el) | Παραγωγα κιναζολινης, φαρμακα που περιεχουν τις ενωσεις αυτες χρηση αυτων και μεθοδους για την παραγωγη τους | |
CY1108544T1 (el) | Παραγωγα πυραζολιου, συνθεσεις που περιεχουν τετοιες ενωσεις και μεθοδοι χρησης | |
CY1105247T1 (el) | Υποκατεστημενα παραγωγα c- κυκλοεξυλομεθυλαμινης | |
ATE478840T1 (de) | 3-aminoazetidinderivate enthaltende pharmazeutische zusammensetzungen, diese derivate und deren herstellung | |
EA200301250A1 (ru) | Фармацевтические композиции, содержащие слаборастворимые и/или чувствительные к кислотам лекарственные средства и нейтрализованные кислотные полимеры | |
CY1110225T1 (el) | Κυκλικοι αναστολεις πρωτεϊνικης τυροσινικης κινασης | |
BR0208338A (pt) | Derivados de piridina | |
CY1112946T1 (el) | 4-υδροξυβενζομορφανια | |
EE200200357A (et) | Ravimaine suurenenud kontsentratsioone andvad farmatseutilised kompositsioonid | |
DE60232660D1 (de) | Humane dr4-antikörper und deren anwendungen | |
CY1107773T1 (el) | Τυποποιησεις που περιεχουν εκτεïνασκιδινη και δισακχαριτη | |
ATE231872T1 (de) | Thiazolopyrimidinderivate | |
DE502004002571D1 (de) | Substituierte 3-pyrrolidin-indol-derivate | |
CO5660287A2 (es) | Derivados de tetrahidrocarbazol y su uso farmaceutico | |
BR0014352A (pt) | Cetoenóis espirocìclicos substituìdos por trifluormetila | |
CY1105225T1 (el) | Παραγωγα 5-β-σαπωγενινης και ψευδοσαπωγενινης και η χρηση τους στην αντιμετωπιση ανοιας | |
UY27455A1 (es) | Derivados n-(1,4,5,6-tetrahidro-ciclopentapirazol -3-il)- sustituidos. su obtención y uso como fármacos. | |
DE60216305D1 (de) | Zusammensetzungen zur verabreichung von arzneimittelkombinationen | |
CY1105019T1 (el) | Υποκατεστημενες c-ιμιδαζο-[1,2-α]πυριδιν-3-υλο-μεθυλαμινες | |
ITRM20030363A0 (it) | Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico diesse. | |
EA200300727A1 (ru) | Производные 2h-1-бензопирана, способы их получения и их фармацевтические композиции | |
HK1065305A1 (en) | Substituted 4-aminocyclohexanol derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |